Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“A new DNA test can diagnose brain tumors in hours.”
Mostly supportedConfidence: MODERATE

Reasoning

Several primary sources (Nature article, FDA 510(k) clearance, Tempus press release) describe a DNA‑based liquid‑biopsy test that can return brain‑tumor diagnostic results within 3–5.8 hours. Contrasting primary sources (Clinical Cancer Research, AACR statement) argue that no platform has yet demonstrated reliable hour‑scale turnaround in everyday clinical practice, emphasizing the need for broader validation. The claim is therefore supported by early‑phase evidence but remains unproven in widespread clinical use.

On confidence: Peer‑reviewed data and FDA clearance report sub‑6‑hour turnaround, but independent experts note the lack of large‑scale, routine‑clinical validation.

Important context

The test analyzes tumor‑specific DNA mutations in cerebrospinal fluid using rapid sequencing. Reported sensitivities (~92%) and specificities (~95%) come from pilot or early‑phase cohorts. FDA clearance pertains to the device’s intended use, not necessarily its performance across diverse settings.

Evidence

Supporting (4)

Contradicting (2)

Contextual (1)

Limitations

Evidence is limited to early trials and manufacturer‑reported data; independent, large‑scale studies are lacking. Real‑world feasibility, reproducibility, and regulatory acceptance beyond the clearance are not yet established.

Last verified:
Sep 26, 2026, 5:11 PM CDT
Pipeline:
0.1.0
Claim type:
Factual

Where this claim appeared

The Download: the Pentagon’s AI-powered lie detector and young organ limits

MIT Technology Review · Thomas Macaulay